TTY Biopharm


Onco Care Pharma


American Taiwan Biopharma
Concise Prescribing Info
Doxorubicin HCl
AIDs-related Kaposi's sarcoma in patients w/ low CD4 (<200 CD4 lymphocytes/mm3) & disease in mucosa, skin & internal organs. Metastasis carcinoma of the ovary in patients w/ disease recurrent to both 1st-line platinum & paclitaxel-based chemotherapy regimens. As monotherapy for patients w/ metastatic breast cancer, where there is an increased cardiac risk.
Dosage/Direction for Use
Breast/ovarian cancer 50 mg/m2 IV once every 4 wk. Dose ≥90 mg: Dilute in 500 mL dextrose 5% in water; <90 mg: Dilute 250 mL dextrose 5% in water. Administer at a rate not >1 mg/min, can be increased to complete admin over a 60-min period. AIDs-related Kaposi's sarcoma 20 mg/m2 IV every 2-3 wk at interval not <10 days to avoid drug accumulation & increased toxicity for 2-3 mth. Dilute 250 mL dextrose 5% in water by IV infusion over 30 min. Hepatic impairment: Bilirubin >3 mg/dL Initially reduce by 50%; 1.2-3 mg/dL Initially reduced by 25%.
Hypersensitivity. AIDS-related Kaposi's sarcoma patients effectively treated by local therapy or systemic α-interferon. Breastfeeding.
Special Precautions
Cardiac toxicity; cardiac impairment; CHF due to cardiomyopathy may occur suddenly. Evaluation test & monitoring of cardiac performance during anthracycline therapy (ECG monitoring, measurement of left ventricular ejection fraction, endomyocardial biopsy). Myelosuppression. Perform periodic blood counts during the course of therapy & at least before each dose. Persistent severe bone marrow suppression may result in recurrent infection hemorrhage. Diabetic patients. Infusion-related adverse reactions. Not recommended w/ pegylated liposomal doxorubicin in patients w/ splenectomy. Avoid driving & machine operations as dizziness & somnolence may occur. Women of childbearing potential. Not recommended during pregnancy. Lactation. Childn <18 yr.
Adverse Reactions
Palmar-plantar erythrodysesthesia. Breast cancer: Nausea. Ovarian cancer: Stomatitis. AIDs-related Kaposi's sarcoma: Bone marrow suppression.
Drug Interactions
May induce toxicity of other anti-cancer drugs. Exacerbates cyclophosphamide-induced hemorrhagic cystitis & enhances hepatotoxicity of 6-mercaptopurine.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01DB01 - doxorubicin ; Belongs to the class of cytotoxic antibiotics, anthracyclines and related substances. Used in the treatment of cancer.
Lipo-Dox soln for inj 2 mg/mL
10 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in